Clinical trials: in Moldova
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Melanoma
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
- Trial name
- NCT06054555
- Testing
- ABP 206, Nivolumab
- Where
- 180 sites in United States, Argentina and 29 more
- Volunteers
- 633 people
- Sponsor
- Amgen
Solid Tumor, Adult
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
- Trial name
- NCT06265727
- Testing
- CRB-701, Anti-PD-1
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 348 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Chronic Hep B, Chronic Hepatitis b
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.
- Conditions
- Chronic Hep B, Chronic Hepatitis b, Chronic Hepatitis, HBV
- Trial name
- NCT06671093
- Testing
- Tune-401
- Where
- 3 sites in Hong Kong, Moldova and 1 more
- Volunteers
- 36 people
- Sponsor
- Tune Therapeutics, Inc.
Ulcerative Colitis
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT02531126
- Testing
- RPC1063
- Where
- 41 sites in United States, Australia and 18 more
- Volunteers
- 877 people
- Sponsor
- Celgene
Rheumatoid Arthritis
SBD121, a Synbiotic Medical Food for RA Management
The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid…
- Trial name
- NCT06005220
- Testing
- SBD121
- Where
- 22 sites in Australia, Bulgaria and 2 more
- Volunteers
- 143 people
- Sponsor
- Solarea Bio, Inc
Systemic Lupus Erythematosus
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
- Trial name
- POETYK SLE-1 (NCT05617677)
- Testing
- Deucravacitinib
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 516 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus…
- Trial name
- NCT05162586
- Testing
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 456 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Adult
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor…
- Trial name
- NCT05586321
- Testing
- GEN1056
- Where
- 7 sites in Georgia, Moldova and 1 more
- Volunteers
- 26 people
- Sponsor
- Genmab
Chronic Hepatitis B
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
The goal of this clinical trial is to learn if ALG-000184 is safe, well-tolerated, and works to treat chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT04536337
- Testing
- ALG-000184, Entecavir
- Where
- 10 sites in Australia, China and 4 more
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Pain, Osteo Arthritis Knee
Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee.
- Conditions
- Pain, Osteo Arthritis Knee, Knee Osteoarthritis, Arthritis
- Trial name
- NCT05618782
- Testing
- LEVI-04
- Where
- 13 sites in Czechia, Denmark and 3 more
- Volunteers
- 518 people
- Sponsor
- Levicept
Crohn Disease
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03440372
- Testing
- Ozanimod
- Where
- 408 sites in United States, Argentina and 33 more
- Volunteers
- 625 people
- Sponsor
- Celgene
Chronic Hepatitis C Virus, Hepatitis C, Chronic
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
- Conditions
- Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis
- Trial name
- NCT05904470
- Testing
- Bemnifosbuvir, Ruzasvir
- Where
- 51 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Crohn Disease
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03464097
- Testing
- Ozanimod
- Where
- 765 sites in United States, Argentina and 47 more
- Volunteers
- 550 people
- Sponsor
- Celgene
Carcinoma, Non-Small-Cell Lung, Gastric Cancer
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04931654
- Testing
- AZD7789
- Where
- 21 sites in United States, Canada and 8 more
- Volunteers
- 136 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA)
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination…
- Trial name
- NCT06671054
- Testing
- AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg
- Where
- 11 sites in United States, Bulgaria and 3 more
- Volunteers
- 240 people
- Sponsor
- SynAct Pharma Aps
Dermatomyositis, Myositis
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants.
- Trial name
- empacific (NCT06284954)
- Testing
- Empasiprubart IV
- Where
- 28 sites in United States, Georgia and 5 more
- Volunteers
- 3 people
- Sponsor
- argenx
Crohn Disease
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03467958
- Testing
- Ozanimod
- Where
- 766 sites in United States, Argentina and 47 more
- Volunteers
- 854 people
- Sponsor
- Celgene
Ulcerative Colitis
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with…
- Trial name
- NCT04857112
- Testing
- Low Dose MT-1303, High Dose MT-1303, MT-1303
- Where
- 185 sites in United States, Australia and 17 more
- Volunteers
- 322 people
- Sponsor
- Bausch Health Americas, Inc.